Search
CXD101
go.drugbank.com/drugs/DB16182InvestigationalCXD101 is under investigation in clinical trial NCT03873025 (A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-cell Lymphoma).
MRK-003
go.drugbank.com/drugs/DB17015ExperimentalMRK-003 is a potent and selective γ-secretase inhibitor developed by Merck. It is the preclinical analog of [MK-0752], a drug in clinical development.[A252682]
Ellipticine
go.drugbank.com/drugs/DB17026ExperimentalEllipticine is a potent antineoplastic agent.[A252992]
GBR-12783
go.drugbank.com/drugs/DB17027ExperimentalA selective inhibitor of dopamine uptake.[A252997]
GSK-269962A
go.drugbank.com/drugs/DB17030ExperimentalGSK-269962A is a Rho kinase (ROCK) inhibitor with both ROCK1 and ROCK2 affinity.[A253012]
Homidium
go.drugbank.com/drugs/DB17031InvestigationalHomidium is a group II compound with trypanocidal effects.[A253017]
Categories: Compounds used in a research, industrial, or household settingNNC-55-0396 free base
go.drugbank.com/drugs/DB17037ExperimentalNNC-55-0396 is a T-type Ca(2+) channel inhibitor.[A253047]
Pristimerin
go.drugbank.com/drugs/DB17049ExperimentalPristimerin is a quinone methide triterpenoid researched for its anti-cancer potential.[A253107]
TPCA-1
go.drugbank.com/drugs/DB17058ExperimentalTPCA-1 is a selective inhibitor of human IκB kinase 2 (IKK-2).[A253152]
Synonyms: Ikk 2 inhibitor iv, Ikk-2 inhibitor ivSepantronium
go.drugbank.com/drugs/DB17062InvestigationalSepantronium is a compound that suppresses survivin expression in a dose and time-dependent manner, and causes broad-range apoptosis.[A253167]
Categories: P-glycoprotein substrates